Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, currently in a Phase 1b trial for celiac disease; and ANB101, a BDCA2 modulator, in a Phase 1a trial [3] - Anaptys has discovered and out-licensed multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals [3] Upcoming Events - Daniel Faga, president and CEO of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 4:30 PM PT / 7:30 PM ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website, with a replay accessible for at least 30 days following the event [2] Strategic Developments - Anaptys recently announced plans to separate its biopharma operations from its substantial royalty assets by year-end 2026, allowing investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company [4]